Get the Stockscreener App
0.4886
4.65%
0.0217
Pre-market:
.57
0.0814
+16.66%
Theriva Biologics Inc stock is traded at $0.4886, with a volume of 16.02M.
It is up +4.65% in the last 24 hours and down -64.59% over the past month.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
See More
Previous Close:
$0.4669
Open:
$0.48
24h Volume:
16.02M
Relative Volume:
14.50
Market Cap:
$4.00M
Revenue:
-
Net Income/Loss:
$-18.35M
P/E Ratio:
-0.4212
EPS:
-1.16
Net Cash Flow:
$-19.20M
1W Performance:
+7.38%
1M Performance:
-64.59%
6M Performance:
-64.59%
1Y Performance:
-99.69%
1-Day Range:
$0.4507
$0.4886
1-Week Range:
$0.402
$0.4886
52-Week Range:
$0.402
$184.31
Theriva Biologics Inc Stock (TOVX) Company Profile
Name
Theriva Biologics Inc
Sector
Industry
Phone
301 417 4364
Address
9605 Medical Center Drive, Suite 270, Rockville
Compare TOVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TOVX
Theriva Biologics Inc
|
0.4886 | 3.52M | 0 | -18.35M | -19.20M | -1.16 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Theriva Biologics Inc Stock (TOVX) Latest News
Theriva?? Biologics Announces Presentation of Data from Vcn-01 Retinoblastoma Phase 1 Clinical Trial At Asco 2025 - marketscreener.com
Theriva Biologics (TOVX) to Present Key Retinoblastoma Trial Data | TOVX Stock News - GuruFocus
Theriva™ Biologics Announces Presentation of Data from - GlobeNewswire
Theriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at ASCO 2025 and Investigator Meeting to Review Topline Data from the VIRAGE Phase 2b Trial of VCN-01 in Metastatic Pancreatic Cancer - Yahoo Finance
Synthetic Biologics stock plunges to 52-week low of $0.47 By Investing.com - Investing.com South Africa
Synthetic Biologics stock plunges to 52-week low of $0.47 - Investing.com Australia
Theriva Biologics: Q1 Earnings Snapshot - Midland Daily News
Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results - GlobeNewswire
Theriva Biologics (TOVX) Achieves Milestone in Pancreatic Cancer Trial | TOVX Stock News - GuruFocus
Theriva Biologics Posts Narrower Loss In Q1 - Nasdaq
Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results | TOVX Stock News - GuruFocus
Breakthrough: New Cancer Drug Shows Survival Benefits in Advanced Pancreatic Cancer Trial Results - Stock Titan
Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients - The Globe and Mail
Theriva Biologics’ (TOVX) Hold Rating Reiterated at Maxim Group - Defense World
Theriva Biologics Shares Plunge After Pricing $7.5M Offering: Retail Sentiment Still Strong - MSN
Theriva Biologics Completes $7.5 Million Public Offering - TipRanks
Theriva Biologics Announces Closing of $7.5 Million Public Offering | TOVX Stock News - GuruFocus
Theriva Biologics Closes $7.5 Million Public Offering to Advance Cancer Therapeutics - Nasdaq
Theriva Biologics Announces Closing of $7.5 Million Public Offering - GlobeNewswire
Theriva Biologics Inc (AMEX: TOVX) Shares Are Set To Rise By 2025 - Stocksregister
Theriva Biologics (TOVX) Faces Downgrade After Phase 2b Study Re - GuruFocus
Theriva Biologics (TOVX) Faces Downgrade After Phase 2b Study Results | TOVX Stock News - GuruFocus
TOVX: Theriva Biologics Downgraded by Maxim Group | TOVX Stock N - GuruFocus
This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga
Theriva’s VCN-01 improves survival in phase IIb pancreatic cancer trial - BioWorld MedTech
Theriva™ Biologics Announces Primary Endpoints for Efficacy - GlobeNewswire
Theriva Biologics sets terms for $7.5 million public offering By Investing.com - Investing.com South Africa
Transcript : Theriva Biologics, Inc.Special Call - marketscreener.com
Theriva?? Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in Virage Phase 2B Clinical Trial of Vcn-01 with Gemcitabine/Nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients - marketscreener.com
Theriva Biologics Announces Pricing of $7.5 Million Public Offering - citybiz
Theriva Biologics (TOVX) Announces $7.5 Million Public Offering - GuruFocus
Theriva Biologics (TOVX) Announces $7.5 Million Public Offering | TOVX Stock News - GuruFocus
Theriva Biologics Announces Pricing of $7.5 Million Public Offering | TOVX Stock News - GuruFocus
Theriva Biologics Announces Pricing of Public Offering for $7.5 Million to Support Cancer Therapeutics Development - Nasdaq
Theriva Biologics sets terms for $7.5 million public offering - Investing.com
Theriva Biologics (TOVX) Reports Promising Phase 2b Trial Results for VCN-01 | TOVX Stock News - GuruFocus
Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients - The Manila Times
Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price Up 6.8% – Should You Buy? - Defense World
Theriva Biologics Announces Presentation of Data from the - GlobeNewswire
Major Clinical Trial Update: Theriva's SYN-004 Shows Promise in Transplant PatientsKey Data Revealed - Stock Titan
Synthetic Biologics stock plunges to 52-week low at $1.02 - Investing.com Australia
Synthetic Biologics stock plunges to 52-week low at $1.02 By Investing.com - Investing.com South Africa
Theriva Biologics Completes Enrollment For VIRAGE Trial, Topline Data Expected In Q2 2025 - Nasdaq
Theriva™ Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company’s Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Ad - GlobeNewswire
Cancer Drug Breakthrough: Independent Committee Confirms Positive Safety Data in Phase 2b Pancreatic Trial - Stock Titan
Theriva Biologics (NYSEAMERICAN:TOVX) Shares Down 1.4% – Should You Sell? - Defense World
Theriva Biologics Inc Stock (TOVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.48%
Cap:
|
Volume (24h):